Iniciativa científica de:

GECP lung cancer research

LUNG CANCER UPDATES

ASCO HIGHLIGHTS

31 MAYO - 4 JUNIO 2019

Con la colaboración de:

Bristol-Myers Squibb

illumina

Lilly

LUNG CANCER
UPDATES
ASCO HIGHLIGHTS
31 MAYO - 4 JUNIO 2019

Iniciativa científica de:
GECP
lung cancer research

CPNM con mutación EGFR

Dr. Bartomeu Massutí

Día 3

Con la colaboración de:

Bristol-Myers Squibb
illumina
Lilly

Combinación EGFR-TKI + Antiangiogénico
EC REPLAY

- EC Fase IIII
- Objetivo primario: PFS evaluada por investigador
- HR 0.71 / 270 eventos
- Objetivos secundarios: OS, RR, DCR, DoR
- Pre-especificados PFS2 y biomarcadores
- En-16-Feb-18
- 449 p

- 100 centros

- En el momento del análisis continúan en tratamiento 19% control vs 29% exper.





Combinación EGFR-TKI + Antiangiogénico
EC REPLAY

LUNG CANCER UPDATES
ASCO HIGHLIGHTS
31 MAYO - 4 JUNIO 2019

RELAY Primary Endpoint: PFS (Investigator-Assessed)



	RAM+ERL n=224	PBO+ERL n=225
Events	122	158
Median, mo	**19.4**	**12.4**
(95% CI)	(15.4–21.6)	(11.0–13.5)
HR (95% CI)	**0.591** (0.461, 0.760)	
P-value	<0.0001	

Consistent PFS benefit by independent, blinded central review (HR 0.671, 95% CI 0.518 – 0.869; p=0.0022)

	RAM+ERL N=224	PBO+ERL N=225
ORR % (95% CI)	76 (71–82)	75 (69–80)
DCR % (95% CI)	95 (92–98)	96 (93–98)
Duration of Response	N=171	N=168
Events	101 (59)	128 (76)
Median, mo (95% CI)	18.0 (13.9–19.8)	11.1 (9.7–12.3)
HR (95% CI)	0.619 (0.477, 0.805)	

- HR 0.65 Del19
- HR 0.62 L858R

- No difs:
  - Tasa de Respuesta
  - Tasa de control enf.

Combinación EGFR-TKI + Antiangiogénico
EC REPLAY

LUNG CANCER UPDATES
ASCO HIGHLIGHTS
31 MAYO - 4 JUNIO 2019

- EAs > G3:
- 72% vs 54%
- No difs. discontinuación tto.
- Aumento diarrea, rash e hipertensión arterial



30-Day FU Post-progression

	RAM+ ERL	PBO+ERL
T790M (+)/patients with results	19/44	35/75
T790M rates (95% CI)	43 (30, 58)	47 (36, 58)
P-value	0.849	



RELAY: PFS2 and Interim OS

		RAM+ERL N=224	PBO+ERL N=225
PFS2	Events,	61	79
	Censoring rate	73%	65%
	Median, mo	NR	NR
	HR (95% CI)	0.690 (0.490, 0.972)	
Interim OS	Events	37	42
	Censoring rate	83%	81%
	Median, mo	NR	NR
	HR (95% CI)	0.832 (0.532, 1.303)	



Combinación EGFR-TKI + QT
Gefitinib vs Gefinitib + Carbo-Pem

- Objetivo primario PFS
- Hipótesis: PFS de 10 a 15 m
  712 p valorados
- 350 p aleatorizados
- EAs G≥3: 50.65% vs 25.3%
- PFS G → 8 m
- PFS G+Cb+P → 16 m
- HR 0.51 (p<0.001)







Alternativas tratamiento CPNM EGFRmut+

LUNG CANCER UPDATES
ASCO HIGHLIGHTS
31 MAYO - 4 JUNIO 2019

How to Integrate the Results of RELAY and Chemo + Gefitinib Trial in the Current Landscape of *EGFR* Mutant Treatment?

- **In the perspective of the whole treatment sequence**



TAK-788 en inserciones Exon 20

LUNG CANCER UPDATES
ASCO HIGHLIGHTS
31 MAYO - 4 JUNIO 2019

- 28 p tratados con 160 mg/24 h
- (6 escalada dosis + 22 cohorte expansión)
- Pretratados (mediana líneas tto. 3)
- 79% tto. previo anti-EGFR
- 43% metas SNC
- Mediana tiempo en tratamiento 7.9 m
- Tasa respuesta 43% / DCR 86%
- mPFS 7.3 m
- 63% EAs G3